Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05787587 · ClinicalTrials.gov registry record · Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by IDEAYA Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 216
- Enrollment target
- 20
- Study locations
NCT05787587: Recruiting Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by IDEAYA Biosciences.
NCT05787587 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 216 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05787587, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by IDEAYA Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 216 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Primary Outcome
* Incidence of Dose Limiting Toxicities * Incidence of treatment-emergent Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy * Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG IDE-161
Study Locations (20)
California
- The Angeles Clinic - Los Angeles
- Hoag Memorial Hospital - Newport Beach
- California Pacific Medical Center - San Francisco
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Columbia University Medical Center - New York
- Weil Cornell University - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- Sarah Cannon Research Institute - Thomas Jefferson University - Philadelphia
Arizona
- HonorHealth Research Institute - Phoenix
Colorado
- Sarah Cannon Research Institute - Denver
Connecticut
- Yale University - New Haven
Florida
- Orlando Health - Orlando
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT05787587 shows while recruiting
NCT05787587 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower).
The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05787587 names 20 study sites across 15 states, led by California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05787587 about?
NCT05787587 is a clinical study titled "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors". The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
What is the current status of trial NCT05787587?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2023-04-18. Estimated completion is 2027-05.
What conditions does trial NCT05787587 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Endometrial Cancer.
What interventions are being tested in trial NCT05787587?
The interventions under investigation include: Pembrolizumab (DRUG), IDE-161 (DRUG).
Who is sponsoring clinical trial NCT05787587?
This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05787587 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05787587's enrollment target sits among peer trials
216 348th of 1224 higher than 877 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI